Skip to main content
Log in

Nonlinear assessment of nitrofurantoin bioavailability in rabbits

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The influence of route of administration on the absolute bioavailability and GI tract absorption of nitrofurantoin was investigated in rabbits. The disposition of nitrofurantoin was described by a one-compartment model with simultaneous first-order and Michaelis-Menten type elimination kinetics, and bioavailability was estimated by nonlinear assessment. The plasma levels following oral administration were significantly lower than those after intravenous administration, and absolute Fvalues for oral administration were approximately 0.3. However, Fvalues following intraduodenal administration and portal vein infusion were nearly unity, and it was concluded that the reduction of bioavailability following oral administration could not be attributed to metabolism by intestinal microflora or to the hepatic first-pass effect. Thus, reduction of Fvalues following oral administration is probably due to gastric degradation of the drug. The effects of factors influencing bioavailability, such as water volume taken with the drug, change of gastric emptying rate and effect of particle size, were also investigated. Increase of volume of water administered tended to improve the bioavailability, and a particle size dependency was also observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G. L. Mattok, R. D. Hossie, and I. J. McGilveray.In vivo:in vitro studies of nitrofurantoin tablets.Can. J. Pharm. Sci. 7:84–87 (1972).

    CAS  Google Scholar 

  2. R. G. Stoll, T. R. Bates, and J. Swarbrick.In vitro dissolution andin vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates.J. Pharm. Sci. 62:65–68 (1973).

    Article  CAS  PubMed  Google Scholar 

  3. T. R. Bates, H. A. Rosenberg, and A. V. Tembo. Inconsistencies in rationale underlying official USP dissolution rate specifications for nitrofurantoin.J. Pharm. Sci. 62:2057–2058 (1973).

    Article  CAS  PubMed  Google Scholar 

  4. T. R. Bates, J. M. Young, C. M. Wu, and H. A. Rosenberg. pH-Dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules.J. Pharm. Sci. 63:643–645 (1974).

    Article  CAS  PubMed  Google Scholar 

  5. I. J. McGilveray, G. L. Mattok, and R. D. Hossie. The comparison of the bioavailabilities of commercial nitrofurantoin tablets.Rev. Can. Biol. 32:99–106 (1973).

    PubMed  Google Scholar 

  6. K. S. Albert, A. J. Sedman, P. Wilkinson, R. G. Stoll, W. J. Murray, and J. G. Wagner. Bioavailability studies of acetaminophen and nitrofurantoin.J Clin. Pharmacol. 14:264–270 (1974).

    Article  CAS  PubMed  Google Scholar 

  7. M. C. Meyer, G. W. A. Slywka, R. E. Dann, and P. L. Whyatt. Bioavailability of 14 nitrofurantoin products.J. Pharm. Sci. 63:1693–1698 (1974).

    Article  CAS  PubMed  Google Scholar 

  8. R. W. Mendes, S. Z. Masih, and R. R. Kanumuri. Effect of formulation and process variables on bioequivalency of nitrofurnatoin II:In vivo-in vitro correlation.J. Pharm. Sci. 67:1616–1619 (1978).

    Article  CAS  PubMed  Google Scholar 

  9. R. Gröning. Control of release and biological availability of drugs—investigations into the renal elimination of nitrofurantoin.Int. J. Pharm. 8:175–181 (1981).

    Article  Google Scholar 

  10. L-K. Chen, D. E. Cadwallader, and H. W. Jun. Nitrofurantoin solubility in aqueous urea and creatinine solutions.J Pharm. Sci. 65:868–872 (1976).

    Article  CAS  PubMed  Google Scholar 

  11. J. A. Buzard, R. C. Bender, E. G. Nohle, D. T. Humphrey, and M. F. Paul. Renal tubular transport of nitrofurantoin.Am. J. Physiol. 202:1136–1140 (1962).

    CAS  PubMed  Google Scholar 

  12. M. F. Paul, R. C. Bender, and E. G. Nohle. Renal excretion of nitrofurantoin (Furadantin).Am. J. Physiol. 197:580–584 (1959).

    CAS  PubMed  Google Scholar 

  13. M. F. Paul, H. E. Paul, R. C. Bender, F. Kopko, C. M. Harrington, V. R. Ells, and J. A. Buzard. Studies on the distribution and excretion of certain nitrofurans.Antibiot. Chemother. 10:287–302 (1960).

    CAS  PubMed  Google Scholar 

  14. D. E. Cadwallader and H. W. Jun. InAnalytical Profiles of Drug Substances, Vol. 3, Flory and Klaus (eds.) Academic Press, New York, 1976, pp. 346–373.

    Google Scholar 

  15. J. D. Conklin and F. J. Hailey. Urinary drug excretion in man during oral dosage of different nitrofurantoin formulations.Clin. Pharmacol. Ther. 10:534–539 (1969).

    CAS  PubMed  Google Scholar 

  16. J. D. Conklin and D. L. Wagner. Excretion of nitrofurantoin in dog hepatic bile.Br. J. Pharmacol. 43:140–150 (1971).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. J. D. Conklin, R. J. Sobers, and D. L. Wagner. Further studies on nitrofurantoin excretion in dog hepatic bile.Br. J. Pharmacol. 48:273–277 (1973).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. M. B. Aufrere, B-A. Hoener, and M. Vore. Reductive metabolism of nitrofurantoin in the rat.Drug Metab. Disp. 6:403–411 (1978).

    CAS  Google Scholar 

  19. N. Watari and N. Kaneniwa. Dissolution of slightly soluble drugs VIII.In vivo drug dissolution in human subjects and rabbits.Int. J. Pharm. 7:307–316 (1981).

    Article  CAS  Google Scholar 

  20. A. N. Martin, J. Swarbrick, and A. Cammarata.Physical Pharmacy, 2nd ed. Lea & Febiger, Philadelphia, 1973, pp. 484–485.

    Google Scholar 

  21. T. R. Bates, J. A. Sequeira, and A. V. Tembo. Effect of food on nitrofurantoin absorption.Clin. Pharmacol. Ther. 16:63–68 (1974).

    CAS  PubMed  Google Scholar 

  22. N. Watari, T. Funaki, and N. Kaneniwa. Fluorescence assay of nitrofurantoin with o-aminothiophenol in plasma and urine.J. Pharm. Sci. 69:106–107 (1980).

    Article  CAS  PubMed  Google Scholar 

  23. J. D. Conklin and R. D. Hollifield. A new method for the determination of nitrofurantoin in urine.Clin. Chem. 11:925–931 (1965).

    CAS  PubMed  Google Scholar 

  24. L. Martis and R. H. Levy. Bioavailability calculations for drugs showing simultaneous first-order and capacity-limited elimination kinetics.J. Pharmacokin. Biopharm. 1:283–294 (1973).

    Article  CAS  Google Scholar 

  25. S. Øie and D. Jung. Bioavailability under variable renal clearance conditions.J. Pharm. Sci. 68:128–129 (1979).

    Article  PubMed  Google Scholar 

  26. T. Nakagawa and Y. Oyanagi. Program system “SALS” for nonlinear least-squares fitting in experimental sciences. InAbstracts, International Conference on Statistics, Tokyo, (November 1979), pp. 19–22.

  27. M. L. Henderson, A. L. Picchioni, and L. Chin. Evaluation of oral dilution as a first acid measure in poisoning.J. Pharm. Sci. 55:1311–1313 (1966).

    Article  CAS  PubMed  Google Scholar 

  28. J. M. Jaffe. Effect of propantheline on nitrofurantoin absorption.J. Pharm. Sci. 64: 1729–1730 (1975).

    Article  CAS  PubMed  Google Scholar 

  29. H. E. Paul, K. J. Hayes, M. F. Paul, and A. R. Borgmann. Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs.J. Pharm. Sci. 56:882–885 (1967).

    Article  CAS  PubMed  Google Scholar 

  30. Y. Imamura, L. H. Wang, C. S. Lee, and J. H. Perrin. Effects of chlorpromazine and atropine on acetaminophen absorption in rabbits.Int. J. Pharm. 5:25–32 (1980).

    Article  CAS  Google Scholar 

  31. J. D. Conklin, R. J. Sobers, and D. L. Wagner. Urinary drug excretion in dogs during therapeutic doses of different nitrofurantoin dosage forms.J. Pharm. Sci. 58:1365–1368 (1969).

    Article  CAS  PubMed  Google Scholar 

  32. W. J. Jusko, J. R. Koup, and G. Alvan. Nonlinear assessment of phenytoin bioavailability.J. Pharmacokin. Biopharm. 4:327–336 (1976).

    Article  CAS  Google Scholar 

  33. J. T. Lettieri and H-L. Fung. Dose-dependent pharmacokinetics and hypnotic effects of sodium γ-hydroxybutyrate in the rat.J. Pharmacol. Exp. Ther. 208:7–11 (1979).

    CAS  PubMed  Google Scholar 

  34. R. K. Liedtke, S. Ebel, B. Missler, W. Haase, and L. Stein. Single-dose pharmacokinetics of macrocrystalline nitrofurantoin formulations.Arzneim. -Forsch./Drug Res. 30:833–836 (1980).

    CAS  Google Scholar 

  35. B. Hoener and S. E. Patterson. Nitrofurantoin disposition.Clin. Pharmacol. Ther. 29:808–816 (1981).

    Article  CAS  PubMed  Google Scholar 

  36. N. Inotsume and M. Nakano. Reversible azomethine bond cleavage of nitrofurantoin in acidic solutions at body temperature.Int. J. Pharm. 8:111–119 (1981).

    Article  CAS  Google Scholar 

  37. J. A. Buzard, J. D. Conklin, È. O'Keefe, and M. F. Paul. Studies on the absorption, distribution and elimination of nitrofurantoin in the rat.J. Pharmacol. Exp. Ther. 131:38–43(1961)

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watari, N., Funaki, T., Aizawa, K. et al. Nonlinear assessment of nitrofurantoin bioavailability in rabbits. Journal of Pharmacokinetics and Biopharmaceutics 11, 529–545 (1983). https://doi.org/10.1007/BF01062210

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01062210

Key words

Navigation